Immunotherapy Innovations in the Fight against Osteosarcoma: Emerging Strategies and Promising Progress

Shigao Cheng,Huiyuan Wang,Xuejia Kang,Hui Zhang
DOI: https://doi.org/10.3390/pharmaceutics16020251
IF: 6.525
2024-02-09
Pharmaceutics
Abstract:Immunosuppressive elements within the tumor microenvironment are the primary drivers of tumorigenesis and malignant advancement. The presence, as well as the crosstalk between myeloid-derived suppressor cells (MDSCs), osteosarcoma-associated macrophages (OS-Ms), regulatory T cells (Tregs), and endothelial cells (ECs) with osteosarcoma cells cause the poor prognosis of OS. In addition, the consequent immunosuppressive factors favor the loss of treatment potential. Nanoparticles offer a means to dynamically and locally manipulate immuno-nanoparticles, which present a promising strategy for transforming OS-TME. Additionally, chimeric antigen receptor (CAR) technology is effective in combating OS. This review summarizes the essential mechanisms of immunosuppressive cells in the OS-TME and the current immune-associated strategies. The last part highlights the limitations of existing therapies and offers insights into future research directions.
pharmacology & pharmacy
What problem does this paper attempt to address?